Literature DB >> 1698597

Complement-fixing antibodies to sympathetic and parasympathetic tissues in IDDM. Autonomic brake index and heart-rate variation.

S L Rabinowe1, F M Brown, M Watts, A M Smith.   

Abstract

We describe herein complement-fixing anti-adrenal medullary (CF-ADM) and anti-sympathetic ganglia (CF-SG) antibodies in insulin-dependent diabetes mellitus (IDDM). This study describes complement-fixing anti-vagus (CF-V) nerve antibodies and their relationship to the cardiovascular autonomic brake index (a measure of transient decrease in heart rate during the 1st min after a tilt), and R-R interval variation with deep breathing. CF-V was detectable in 7 of 83 (8.4%) subjects with IDDM aged 1.5-65.5 yr (mean +/- SE 28.7 +/- 1.8 yr) and duration of diabetes 0-47 yr (11.8 +/- 1.4 yr). Seventy-six nondiabetic subjects (aged 10-65 yr) all had negative CF-V scores. CF-V scores correlated with CF-ADM (0-16 yr of IDDM, r = 0.61, P less than 0.0001) and CF-SG (r = 0.39, P less than 0.05). Seventy IDDM subjects (aged 28 +/- 5 yr, duration of diabetes 17 +/- 3 yr) without proteinuria or proliferative retinopathy were screened for CF-ADM, CF-SG, and CF-V antibodies. Five of 70 (7.1%) had CF-SG only (negative for CF-ADM and CF-V). Brake indices ranged from 14.7 to 51.3 (37.3 +/- 6.9). Three of 70 (4.2%) had CF-ADM only, with brake indices from 26.9 to 45.1 (32.9 +/- 6.1). Four of 70 (5.7%) had CF-V antibodies only, with brake indices of 12.7-17.3 (15.1 +/- 1.1). Subjects with CF-SG or CF-ADM (anti-sympathetic) had higher brake indices than subjects with CF-V (anti-parasympathetic) antibodies (P less than 0.03).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698597     DOI: 10.2337/diacare.13.10.1084

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

Review 1.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

2.  [Cardiovascular and pupillary autonomic and somatosensory neuropathy in chronic diseases with autoimmune phenomena. A comparative study of patients with Crohn disease, ulcerative colitis, systemic lupus erythematosus, progressive systemic sclerosis and type I diabetes mellitus].

Authors:  R H Straub; T Andus; G Lock; M Zeuner; K D Palitzsch; V Gross; B Lang; J Schölmerich
Journal:  Med Klin (Munich)       Date:  1997-11-15

3.  Glutamic acid decarboxylase antibodies, autonomic nerve antibodies and autonomic neuropathy in diabetic patients.

Authors:  G Sundkvist; L A Velloso; O Kämpe; S L Rabinowe; S A Ivarsson; B Lilja; F A Karlsson
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

4.  Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy.

Authors:  R E Schmidt; D A Dorsey; L N Beaudet; S B Plurad; C A Parvin; M S Miller
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 5.  Cardiac autonomic neuropathy in patients with diabetes mellitus.

Authors:  Gerasimos Dimitropoulos; Abd A Tahrani; Martin J Stevens
Journal:  World J Diabetes       Date:  2014-02-15

6.  Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients.

Authors:  O Schsnell; D Muhr; S Dresel; K Tatsch; A G Ziegler; M Haslbeck; E Standl
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

7.  Autoantibodies to nervous tissue structures are associated with autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus.

Authors:  M M Zanone; M Peakman; T Purewal; P J Watkins; D Vergani
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

8.  Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy.

Authors:  Robert E Schmidt; Denise A Dorsey; Lucie N Beaudet; Kathy E Frederick; Curtis A Parvin; Santiago B Plurad; Matteo G Levisetti
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.